Immune tolerance with combined allogeneic haplo-identical haematopoietic stem cell transplant and renal transplant. Read more about Immune tolerance with combined allogeneic haplo-identical haematopoietic stem cell transplant and renal transplant.
Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation. Read more about Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation.
Induction of therapeutic levels of HbF in genome-edited primary β0 39-thalassaemia haematopoietic stem and progenitor cells. Read more about Induction of therapeutic levels of HbF in genome-edited primary β0 39-thalassaemia haematopoietic stem and progenitor cells.
Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. Read more about Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma.
Fatigue in children and adolescents with immune thrombocytopenia. Read more about Fatigue in children and adolescents with immune thrombocytopenia.
Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents. Read more about Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents.
Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities. Read more about Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities.
Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma. Read more about Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma.
Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. Read more about Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma.
Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. Read more about Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.
